Preterm delivery Pregnancy and Childbirth Complications of labour and delivery
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Phase 1 Clinicians who work in hospitals with neonatal intensive care units (any of the following): 1. Consultant obestricians 2. Neonatologists 3. Midwives Members of the public: 1. Interested in supporting and commenting on research projects Phase 2 Clinicians with 5 years or more experience of providing clinical care to women at risk of preterm labour or preterm infants born (any of the following): 1. Obstetricians 2. Anaesthetists 3. Midwives 4. Nurses 5. Neonatologists 6. Midwives Women and their partners who fulfill the following criteria: 1. Aged 16 years or older 2. Willing to consent 3. Previous experience of any of the following: 3.1. Previous preterm labour or delivery 3.2. At risk of future preterm labour or delivery Phase 3 Clinicians with 5 years or more experience of providing clinical care to women at risk of preterm labour or preterm infants born (any of the following) who have taken part in phases 1 and 2: 1. Obstetricians 2. Anaesthetists 3. Midwives 4. Nurses 5. Neonatologists 6. Midwives Women who fulfill the following criteria: 1. Aged 16 years or older 2. Willing to consent 3. Previous experience of any of the following: 3.1. Previous preterm labour or delivery 3.2. At risk of future preterm labour or delivery
Exclusion criteria
Exclusion criteria: Phase 2 and 3 Women and their partners who have experienced adverse events as a result of the issues above (e.g. neonatal death, stillbirth) will not be actively excluded from the consensus workshops or focus groups, but we will be mindful of the need to manage this sensitively. The members of the research team have significant experience of conducting mixed-methods research with parents who have experienced adverse events, including perinatal death.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase 1: Current practice and opinions, assessed using surveys conducted during months 0-4 informing the Delphi consensus Phase 2: Clinical uncertainties, assessed using a Delhi consensus conducted during months 5-9 informing the development of a randomised control trial protocol to be used in phase 3 Phase 3: 1. Willingness to recruit to a randomised controlled trial, assessed through interviews with clinical staff during months 10-22 2. Willingness to participate in a randomised controlled trial, assessed through focus groups during months 10-22 | — |
Countries
England, Scotland, United Kingdom